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Reduction of postprocedure microemboli
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angioplasty and stenting
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Barton Lane, MD,c and Jason T. Lee, MD,a Stanford, Calif; and Houston, Tex
Objective: We have previously demonstrated a 70% incidence of microemboli on diffusion weighted magnetic resonance
imaging (DW-MRI) following carotid angioplasty and stenting (CAS). The purpose of this study is to compare the
incidence of microemboli in two distinct time periods when procedural modifications were implemented into a CAS
program.
Methods: Following a retrospective quality review of our CAS cohort (n 27) from November 2004 through April 2006
(period 1), we enrolled patients (n  20) from May 2006 through February 2008 (period 2) undergoing CAS into a
prospective cohort that included obtaining pre- and postprocedure DW-MRI exams. Procedural modifications during
period 2 included the preferential use of closed-cell systems (60% vs 0% in period 1), early heparinization at the initiation
of arterial access, and elimination of an arch angiogram. The hospital records of these 47 patients were reviewed;
symptoms, comorbidities, lesion characteristics, periprocedural information, and postoperative outcomes were collected.
The incidence and location of acute, postprocedural microemboli were determined using DW-MRIs.
Results: Twenty (74%) CAS patients from period 1 and seven (35%) patients from period 2 demonstrated acute
microemboli on postprocedural DW-MRI (P .02). Themean number of microemboli in period 1was 4.1 5.3 vs 1.5
2.7 during period 2 (P .04). Two of the 27 patients (7.4%) during period 1 experienced temporary neurologic changes
that resolved within 36 hours. None of the patients during period 2 exhibited any neurologic changes. Patient
demographics, comorbidities, and presenting symptoms were similar between the two groups except for smoking
prevalence, female presence, and obesity (BMI > 30). Period 2 patients when compared with period 1 had more
technically challenging anatomywithmore calcified lesions (68% vs 27%), longer lesions (15.9mm vs 8.2mm), and higher
incidence of ulceration (55% vs 27%) (all P < .04).
Conclusion: Despite successful performance of 47 consecutive CAS procedures without permanent neurologic sequelae,
significant reductions in periprocedural embolic events as identified via DW-MRI lesions may be achieved through
implementation of quality improvement measures identified through continuous outcome analysis. The long-term
neurologic benefits associated with reduced subclinical neurologic events remains to be determined. (J Vasc Surg 2009;
49:607-13.)Stroke is a leading cause of morbidity and mortality in
the United States.1 Strokes most frequently result from
acute ischemia, 20% of which are due to atherosclerotic
occlusive disease in the carotid artery.2 Carotid angioplasty
and stenting (CAS) is considered a less invasive, effective
treatment strategy for high-risk patients undergoing ca-
rotid revascularization when compared with traditional
open carotid endarterectomy (CEA).
We previously demonstrated an increase in the postpro-
cedure occurrence of cerebral microemboli detected using
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MRI) following CAS compared to CEA. Our initial report
included 27 CAS patients and 20 CEA patients all studied
with pre and postoperative DW-MRI from 2004 to 2006.3
A higher incidence of microemboli was noted in the CAS
cohort over the CEA patients (70% vs 0%, P .0001), and
although no permanent neurologic sequelae were noted in
our CAS experience, a prospective study of DW-MRI le-
sions after CAS was undertaken to determine the possible
effect of several procedural modifications in our CAS tech-
nique.
Hypotheses for the significant postproceduremicroem-
bolic load after CAS have been noted by several authors and
focus on patient, anatomic, and procedural characteris-
tics.3-7 Multivariate analysis revealed that a history of cor-
onary artery disease (CAD) was a significant predictor for
the development of microemboli, suggesting that athero-
sclerotic burden is correlated with plaque instability.7 Uni-
variate analysis in our initial report revealed that performing
routine arch angiography was associated with a higher risk
of microemboli.3 The finding that microemboli can con-
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that stent design may be related to this occurrence.8 What
remains even more unknown is the long-term clinical se-
quelae of these microemboli, since obvious neurologic
deficits measured by 30-day stroke/death rates after CAS
have steadily improved with refinements in the technique
and operator experience.
It is against this backdrop that we implemented a
prospective quality improvement program in an attempt to
reduce the incidence of postprocedure microemboli. The
purpose of this study was to determine if these newly
implemented strategies would decrease the occurrence of
postprocedural microemboli following CAS by comparing
two distinct time periods in the same institution.
METHODS
Carotid angioplasty and stenting. From 2004 to
2007, patients were offered CAS when standard high-risk
criteria for CEA were present, including previous neck
surgery, previous CEA, high C2 lesions, severe active CAD,
or the inability to tolerate general anesthetic. Symptomatic
patients with ultrasound evidence of 70% stenosis or
asymptomatic patients with great than 80% stenosis were
offered carotid revascularization.
The preprocedural anticoagulation regimen for all pa-
tients in both study periods consisted of ASA 81 mg and
clopidogrel 300mg 12 hours prior to the procedure or ASA
81 mg and clopidogrel 75 mg daily for 1 week prior. All
procedures were performed in a dedicated endovascular
suite utilizing biplanar angiography under local anesthesia
and i.v. sedation with arterial monitoring. At least two of
the coauthors were present on the cases (R.L.D., W.Z.,
S.M.C., or J.T.L.) and each had completed their training
cases and was fully credentialed to perform CAS indepen-
dently (range of experience 25 to 200 prior cases). Access
was always from a femoral approach. Arch angiography at
the time of the procedure was performed in patients based
on the preference of the surgeon performing the interven-
tion in period 1, typically using a 5F pigtail catheter (An-
giodynamics, Queensbury, NY) in the ascending aorta and
the arch run completed with 30 mL of contrast at a rate of
15mL/s. After the arch anatomy was laid out, catheteriza-
tion of the target common carotid artery was obtained
using a hydrophilic glidewire over a 6.5 Cook selective
catheter (JB1, H1, or Vitek; Cook Inc, Bloomington, Ind).
In tortuous arteries, the external carotid artery was cannu-
lated prior to advancing the Shuttle sheath into the com-
mon carotid artery. Once access up to the carotid bifurca-
tion was achieved, a 6F Shuttle sheath (Cook Inc,
Bloomington, Ind) was advanced in a triaxial fashion and
the patient was then systemically heparinized to maintain
an activated clotting time (ACT)  300 seconds in period
1. In period 2, full anticoagulation was initiated immedi-
ately upon femoral artery access.
During period 2, a major change in our CAS program
was that arch anatomy was carefully evaluated on preoper-
ative magnetic resonance angiogram (MRA) to determine
arch type, presence of calcification or tortuosity, and pre-procedural planning. Arch angiography was performed se-
lectively and rarely in period 2, only when there was diffi-
culty in cannulating the appropriate branch off the arch
with the catheters mentioned above. Diagnostic arch an-
giogram was performed in 14 (52%) patients in period 1,
compared with three (15%) patients in period 2 (P  .02).
Another major procedural modification in period 2 was the
early heparinization, performed as soon as arterial access in
the groin was achieved.
The Acculink carotid stent system, a self-expanding,
open cell stent, (Guidant, Inc, Sunnyvale, Calif) along with
its Accunet distal protection device was used in all cases in
period 1. During period 2, the Xact (Abbott Vascular,
Redwood City, Calif) carotid stent system became available
and was utilized more often than other stent systems along
with its Emboshield distal protection device. The Xact stent
is a self-expanding, but closed cell stent design, and was
used in twelve (60%) of the cases in period 2. The Acculink
system was utilized in seven (35%) of the period 2 cases,
along with one case utilizing the Precise carotid system
(Cordis Corporation, Warren, NJ).
In both periods 1 and 2, pre- and poststent cervical and
intracranial angiograms were performed. After the target
lesion was visualized and confirmed, predilation was per-
formed in all patients (100%) during both periods 1 and 2
with a 4  20 mm balloon. Following stent deployment,
lesions were often postdilated using a 5 20mm balloon if
there was evidence of residual stenosis (41 out of 47 pa-
tients, 87%). Completion cervical and intracranial angio-
grams were performed in all patients. A 6F Perclose Pro-
glide device (Abbott Vascular, Sunnyvale, Calif) was
utilized based on surgeon preference and suitable femoral
artery anatomy. At the end of the procedure, heparin
reversal with protamine was performed in most patients
based on surgeon preference.
MRI imaging examination. All patients undergoing
intervention had a pretreatment MRI and a post-treatment
MRI performed within 48 hours of the procedure. The
majority (80%) of the post-treatment DW-MRIs were
obtained the following morning (18 to 24 hours postpro-
cedure). Imaging was performed with a 1.5-T apparatus
(GE Signa Excite HD 12.0, GE Healthcare, Chalfont St
Giles, UK) equipped with a head coil utilizing the same
software for both periods 1 and 2. The pre- and post-
treatmentMR imaging routinely included the following: axial
spin-echo T1-weighted, fast-spin echo T2-weighted, fluid-
attenuated inversion-recovery (FLAIR), DW, perfusion-
weighted, and postcontrast spin-echo T1-weighted imag-
ing. The DW images were acquired with an echo-planar
sequence. An isotropic sequence was used (6500/97/1
TR/TE/NEX, field of view 280 mm, matrix 128  128,
with b values of 0 and 1000 s/mm2).
The DW-MR images were then evaluated by neurora-
diologists blinded to the clinical status or periprocedural
outcomes of the patients. Any presence of new hyperinten-
sity in the brain was interpreted as a new ischemic lesion
noted as a microembolism. Microemboli were recorded in
terms of location and number for all exams performed.
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fordHumanResearch Protection Program. Patient character-
istics, including age, symptoms, smoking history, hyperlipid-
emia as defined by the use of a lipid lowering medications,
history of coronary artery disease, peripheral vascular disease,
diabetes mellitus and hypertension as defined by the use of
antihypertensive medications, and obesity defined as body
mass index greater than 30 were collected retrospectively. We
also investigated the records for a history of prior carotid
intervention, history of contralateral stenosis, history of
stroke, and symptoms of the current disease process.
Lesions characteristics including degree of stenosis,
lesion length, calcification, ulceration, and arch anatomy
determined by a combination of preoperative duplex ultra-
sound, MRA, or intraoperative angiography was recorded.
Degree of stenosis was determined using NASCET crite-
ria.9 Lesion length was measured along the vessel where it
was narrowed greater than 50%. Arch anatomy was graded
using Schneider’s classification.10 Lesion calcification was
determined by presence of shadowing on preoperative du-
plex and confirmation under fluoroscopy during the proce-
dure that at least 50% of the circumference of the vessel was
involved for a length of at least one centimeter of the
treated region. Procedure-specific CAS data included total
contrast used, fluoroscopy time, and the use of arch angiog-
raphy. Periprocedural neurologic status (defined as up to
48 hours following the procedure) was determined based
on review of the entirety of the medical record (anesthetic
record, progress notes, nursing notes, discharge summa-
ries, and subsequent outpatient examinations).
Statistical analysis. All data were collected on closed-
response data collection instruments and entered into an
electronic spreadsheet (Microsoft Excel, Microsoft Corpo-
ration, Redmond, Wash). Statistical analyses were per-
formed Excel software or MedCalc version 9.2.1.0 (Med-
Calc Software, Mariakerke, Belgium). Descriptive statistics
were calculated for all variables. Continuous data are re-
ported as median with interquartile ranges or means 
standard deviations, while categorical data are reported as
percentages. Bivariate statistical techniques, including the
Wilcoxon rank sum test and Fisher exact test, were used
when appropriate. Independent group t tests were used to
test mean differences in outcomes between periods. Statis-
tical significance was defined by a P value  .05.
RESULTS
Twenty-seven consecutive patients underwent CAS
with preoperative and postoperative DW-MR imaging in
period 1, and 20 consecutive patients underwent CAS with
preoperative and postoperative DW-MR imaging in period
2 at a single institution. In period 1, the median patient age
was 69 (IQR: 53 – 83) vs 72 years (IQR: 54 – 91) (P .2).
Demographics of the patients undergoing treatment in the
two time periods are summarized in Table I. There was a
higher rate of current smokers in period 1 (96 %) vs period
1 (67%, P  .01). There were no other differences in
patient characteristics between the two time periods. Theincidence of patients with prior CEA on the target lesion
was 37% in period 1 and 45% in period 2 (P  .8).
Lesion characteristics were significantly different be-
tween periods 1 and 2 with respect to incidence of lesion
calcification (30% vs 70%, P  .003), lesion length (8 mm
vs 16 mm, P  0.01), and lesion ulceration (26% vs 60%,
P .01). Median fluoroscopy time was similar between the
two periods (20.1 vs 20.4 minutes, P .5). A greater mean
volume of contrast was used in period 1 compared with
period 2 (76 vs 58 mL, P  .02). With respect to proce-
dural modifications, during period 1, none of the patients
received closed cell stents, while in period 2, 12 (60%) (P
.001) of the CAS cases were performed using a closed cell
stent system (Xact stent). Diagnostic arch angiogram was
performed in 14 (52%) patients in period 1, compared with
three (15%) patients in period 2 (P  .02). The lesion and
procedure characteristics are summarized in Table II.
Twenty patients (74%) from period 1 and seven (35%)
Table I. Patient demographics in the 27 patients in






(n  20) P value
Age 69 72 .2
Female 0 10% .05
Tobacco 97% 65% .01
DM 41% 60% .1
HTN 93% 90% .4
Hyperlipidemia 96% 95% .4
Obesity 19% 40% .05
CAD 85% 85% .5
COPD 33% 30% .4
Prior CEA 37% 45% .8
Symptomatic 48% 45% .4
CAS,Carotid angioplasty and stenting;DM, diabetes mellitus;HTN, hyper-
tension; CAD, coronary artery disease; COPD, chronic obstructive pulmo-
nary disease; CEA, carotid endarterectomy.
Table II. Anatomic and procedural characteristics in the
27 patients in period 1 undergoing CAS vs the 20





(n  20) P value
Lesion calcification 30% 70% .003
Lesion length (mm) 8.2 15.8 .001
Lesion ulceration 26% 60% .001
Type II/III arch 41% 25% .66
Procedural characteristics
Fluoroscopy time (min) 20.2 20.4 0.5
Contrast volume (mL) 76 58 .02
Performance of arch angiogram 52% 15% .02
Number of stents used 1.07 1.15 0.2
Percent of closed cell stent
utilization
0% 60% .001
CAS, Carotid angioplasty and stenting.from period 2 demonstrated evidence of acute postoperative
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Themean number of microemboli in period 1was 4.1 5.3
vs 1.5  2.8 during period 2 (P .02). Of the 20 period 1
patients who demonstrated microemboli, 10 patients (50%)
demonstrated only ipsilateral microemboli, eight (40%) had
bilateral, and two (10%) had only contralateral microemboli.
Of the seven period 2 patients who had microemboli, five
patients (72%) demonstrated ipsilateral microemboli, two
(28%) showed bilateral, and there were no patients who had
only contralateral lesions. The microemboli distribution dif-
ferences were not statistically significant different between the
two study periods.
Two period 1 patients who had microemboli also ex-
perienced periprocedural neurologic sequelae (7.4%) vs
none (0%) of the period 2 patients (P .65). In both cases,
the neurologic changes were transient and resolved within
36 hours. By discharge, they were completely asymptom-
atic and had returned to baseline neurologic status after
being evaluated by an inpatient neurology team. As a
predictor of neurologic events after CAS, microemboli on
DWI demonstrated a sensitivity of 66%, specificity of 29%,
and a negative predictive value of 88%. One patient with 12
microemboli (six contralateral) experienced ataxia and dip-
lopia that resolved within 36 hours of the procedure. A
second patient with 20 microemboli (one contralateral)
experienced contralateral weakness in the upper and lower
extremities resolving within 36 hours after CAS.
Subset analyses of the microemboli outcomes with
respect to open vs closed cell systems and octogenarian
status was also performed (Table IV). There was no differ-
ence in the incidence or number of microemboli between
patients who received a closed cell vs an open cell system
over the entire study period, or when compared within
period 2 independently when other changes in procedural
technique were implemented. Similarly, there was no dif-
ference in these values when we compared patients 80 years
Table III. Outcomes of postprocedural DW-MRI after





(n  20) P value
Incidence of any
microemboli
20 (74%) 7 (35%) .003
Presence of ipsilateral
microemboli
18 (67%) 7 (35%) .06
Presence of contralateral
microemboli
10 (37%) 2 (10%) .07
Mean number of
microemboli
4.1  5.3 1.5  2.8 .02
Temporary neurologic
symptoms
2 (7.4%) 0 (0%) .65
30-day stroke/death 0 0 1.0
CAS, Carotid angioplasty and stenting;DW-MRI, diffusion-weighted mag-
netic resonance imaging.
The two patients with postprocedure neurologic changes had transient
symptoms that resolved within 36 hours.of age and over with patients under the age of 80.DISCUSSION
We have demonstrated a significant reduction in post-
procedural microemboli with the implementation of several
strategies as part of a quality improvement plan within our
CAS program. These strategies include early heparinization
as soon as access is initiated in the femoral vessel, elimina-
tion of routine arch angiography, and the preferential use of
closed cell carotid stent systems. This quality improvement
plan was developed after a significant incidence of DW-
MRI detected lesions was found, despite having acceptable
stroke rates early in our CAS experience.3
As institutions and operators have gained more experi-
ence with CAS, the likelihood of treating more challenging
anatomy and potentially sicker patients is expected. Con-
tinuous outcome analysis during implementation of new
technology and procedures is an important adjunct to
developing quality improvement measures and modifying
techniques. The presence of more severe anatomic risk
factors in period 2 vs period 1 in this study population of
CAS patients in terms of calcified lesions, ulcerated lesions,
and mean length of lesions highlights this observation.
Despite arguably treating more difficult lesions, implemen-
tation of several relatively simple modifications to our CAS
program diminished the postprocedural incidence of acute
microemboli. Reduction of complications postprocedure
intuitively provides benefits in terms of patient outcomes,
but has also been shown previously with open carotid
surgery to lower hospital costs.11 What remains in question
is the long-term significance of DW-MRI detected micro-
emboli.
Several reports have identified microemboli rates to
increase between 24 and 72 hours following carotid inter-
vention, particularly carotid stenting.8,12-14 A possible the-
ory for this is that the plaque that has been disrupted by the
stent and continues to generate microemboli for up to 3
days following the procedure. Again, because the long-
term sequelae of these often asymptomatic lesions are un-
known, the importance of detecting these lesions is called
into question. No current study exists that has followed the
Table IV. Subset analysis of entire cohort (n  47) to
determine whether closed cell stent systems (used more
often in period 2) had an overall effect on incidence or











Closed cell (n  12) 45.4% 0.63 1.5 0.12
Open cell (n  35) 59.4% 3.4
Age 80 (n  41) 56.1% 0.98 2.97 0.32
Age 80 (n  6) 66.7% 3.83
DW-MRI, Diffusion-weighted magnetic resonance imaging.
Octogenarians also did not have a difference in outcomes related to micro-
emboli detected by DW-MRI.lesions or patients for any significant amount of time post-
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long-term effects of the DW-MRImicroemboli, in order to
optimize detection of post-CAS lesions, the scans should be
obtained at the 24 to 48 hour postprocedure mark.
Since the microemboli may be occurring during the
procedure or in the immediate poststent time period, some
have hypothesized that changes in the stent structure can
affect embolic potential. There are reports of observed
differences in postprocedure neurologic sequelae between
open cell and closed cell carotid stent systems.4 A European
report of a retrospective registry of 3179 consecutive CAS
procedures compared stroke outcomes of open and closed
cell stents and found a significant reduction in postproce-
dure major events using a closed cell system (1.3%) com-
pared with an open cell system (3.4%).4 In this study, the
Xact (Abbott Vascular, Sunnyvale, Calif) system was asso-
ciated with one of the lowest postprocedural event rates
(1.9%) in the symptomatic patient population, with the
Wallstent system (Boston Scientific, Natick, Mass), another
closed-cell CAS system, having the lowest postprocedure
major event rate (1.2%). Further analyses demonstrated
that free cell area positively correlated with the incidence of
postprocedural events. In other words, the more the stent
scaffold was exposed, the greater the risk of postprocedural
neurologic events.
With these reported studies about improvements when
using closed cell stent systems as well as the opportunity to
participate in post approval registry trials, we began to use
the Xact stent in period 2 and noted early on that the
incidence of microemboli was on the decline. However,
subset analyses of our data of open vs closed cell stents for
the entire study period or even just within period 2 do not
show a statistically significant difference in microemboli
incidence or mean number of microemboli (Table IV).
Given this is a report of our early experience with closed cell
systems, this may simply represent a type II error.
Another change from period 1 to period 2 was based on
our initial retrospective report3 demonstrating that the
performance of arch angiography was associated with an
increased risk of postprocedural microemboli. In our pro-
spective cohort during period 2, we abandoned routine
arch angiography when performing CAS. Reviewing the
preoperative MRA allowed us to visualize the arch and plan
well enough to cannulate the target arch vessel in the
majority of the cases. The presence of contralateral micro-
emboli in many of the period 1 patients (37%) suggests that
manipulation around the arch or predeployment maneu-
vers including performing arch angiography, excessive
catheter and wire handling, and calcified arches may be
associated with the incidence of DW-MRI lesions. Recent
reports have also correlated arch calcification with a higher
incidence of microemboli, corroborating the hypothesis
that some microemboli can develop during simple arch
manipulation.14 While determining the sole effect of a
single quality improvement measure would have been dif-
ficult in our small series to determine, we believe that the
implementation of a series of these changes in our CAS
program contributed to the significant reduction in post-procedure microemboli: elimination of routine use of arch
angiography, early heparinization, and preferential use of a
closed cell system.
CAS in octogenarians continues to be an extremely
high-risk group of patients where several studies have called
into question the utility of treating these patients. CAS in
this population has been associated with increased risk of
stroke and death rates.5,6,15,16 We could postulate that
octogenarians with their more calcified aortic arches, more
challenging anatomy, and less tolerance to ischemic insults
might have higher incidences of microemboli as their ex-
planation for poorer results. This has not yet been deter-
mined in the literature, and our results again are limited by
small numbers of patients (Table IV). No difference be-
tween the two age groups could be determined in our small
cohort.
Cerebral protection devices have been proposed as a
useful adjunct to limiting microemboli formation after
CAS. However, even in the setting of cerebral protection
devices, such as in the present study, microemboli do occur.
The utility of distal protection device (DPD) in preventing
periprocedural emboli following CAS is moderately well
supported.17 In the SAPPHIRE trial, CAS with DPD
resulted in a major ipsilateral stroke rate at 1 year of 0.6%,
minor ipsilateral stroke rate of 3.8% and minor nonipsi-
lateral stroke rate of 1.9%,18 confirming that intraopera-
tive DPD deployment does not eliminate embolic risk, at
least for the current generation of DPDs. The develop-
ment of microemboli in the first 24 hours after the CAS
procedure when the DPD has long been removed from
the patient presents several challenges for future technol-
ogy improvements to stent and DPD design as well as
procedural modifications.
As continued improvements are being made to CAS,
the procedure will continue to be compared and offered up
against surgical revascularization. One of the challenges in
determining superiority or noninferiority of either of these
strategies for stroke reduction remains the overall low
incidence of postprocedure neurologic events. Structuring
clinical trials or institutional retrospective series to deter-
mine the optimal carotid revascularization procedure is
hampered by the large number of patients and procedures
required to detect a statistically significant difference.
Therefore, alterations in devices, stent modifications, next
generation systems, and procedure modifications will have
difficulty coming to the forefront to improve upon already
arguably excellent clinical results for this technology. The
fact that cerebral microemboli detected on DW-MRI occur
at such a higher incidence may make it a useful marker for
cerebral ischemia that can be used in future comparison
studies. Characterization of these lesions, the distribution,
its risk factors, and the long-term significance will be im-
portant in studying microemboli formation after carotid
interventions.
There are several limitations to this study in addition to
the aforementioned small sample size. Only 12 of the
patients during period 2 received a closed cell system, and
15% of the patients in period 2 did undergo arch angiogra-
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heterogeneous mix. Further limitations revolve around the
study design; this is a single center, retrospective review
initially in which the prospective portion has only been the
past 2 years. A larger, perhaps multicenter, and definitely
prospective study would be necessary to establish the rela-
tionship between these recommended procedural modifi-
cations and their effect on limiting microemboli formation
following CAS.
Furthermore, we cannot discount a learning curve ef-
fect that may have contributed to decreased microemboli
over the course of our CAS program. Of note, each of the
carotid surgeons listed here had extensive prior CAS (range
25 to 200 independent cases as primary operator) and
peripheral endovascular experience before their cases were
counted in either period 1 or period 2. While the reduction
in microemboli may simply be a reflection of improved
wire-handling skills and careful attention to the technical
aspects of the procedure, the major changes implemented
likely have contributed to the overall final effect.
In summary, despite successful performance of 47 con-
secutive CAS procedures without permanent neurologic
sequelae, there still remains a significant incidence of post-
procedure microemboli after CAS. Through implementa-
tion of quality improvement measures, there has been a
significant reduction in periprocedural embolic events as
identified via DW-MRI lesions. The long-term neurologic
and cognitive benefits associated with reduced subclinical
neurologic events remains to be determined.
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Dr Vikram Kashyap (Cleveland, Ohio). As we have heard
earlier in the Society of Vascular (SVS) meeting and earlier in this
session, the national trends for stroke after carotid artery stenting
are somewhat troubling. Dr. Tedesco and her colleagues have
rigorously applied quality improvement techniques to decreaseusing closed cell stents, systemic heparinization, and eliminating
arch arteriography. This led to a reduction in cerebral microem-
boli. I have some questions and comments for the authors.
Can you reiterate for us just the pure difference in outcomes
between open and closed cell stents? If I understood correctly,
there was about a 20% decrease in the microemboli, but that was
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and that with increased experience that you will show that there is
a benefit in a certain stent design?
Secondly, DW-MRI is highly sensitive in picking up cerebral
lesions that do not appear to have any clinical sequelae. Is this
purely a research imaging modality or is there some clinical rele-
vance to using it?
Do you have plans or have you already acquired any late
DW-MRI imaging? This may give us some insight into the plastic-
ity of the brain.
And lastly, you have performed about 50 carotid stenting
procedures over 4 years by three operators. Can your improve-
ments in outcomes be simply increased operator experience rather
than the quality assessment techniques that you instituted?
Dr Tedesco. First, we did perform subset analysis during
period 2 to look at the isolated contribution of using the closed
cell vs the open cell system and did not find a significant
difference in the incidence or total number of microemboli. We
believe the combination of the quality improvement measures,
namely the preferential use of closed cell stents, early hepariniza-
tion, and the elimination of routine arch angiography, all contrib-
uted to the overall significant reduction in total microemboli.
Secondly, with regards to the DW-MRI lesions, we know that
they may disappear by 14 days, but we do not know the long-term
significance. Many authors have suggested since adverse neuro-
logic outcomes are so rare with carotid revascularization proce-
dures, that DW-MRI lesions can be used as a surrogate for out-
comes following CAS vs CEA in future clinical trials. We really do
not understand the clinical significance and the long-term impli-
cations of these microemboli, which may be cognitive decline, loss
of independent living, etc. We will continue to study the long-term
effects of these lesions by performing postprocedure neuropsycho-
logic testing. Furthermore, we have started performing long-term
DW-MRI imaging, at 6 months or a year to follow these patients.
The question about operator experience is an important one.
In reviewing our series, our group was past the learning curve
already prior to the initiation of our study. Each operator has
performed their 25 learning curve cases prior to the study being
initiated with pre- and postprocedure DW-MRI. So we do not
believe we are seeing improvement in technical performance solely
based on operator experience.
Dr Martin Back (Tampa, Fla). There is pretty good cardio-
thoracic literature that shows cognitive declines in patients from
microemboli that occur during cardiopulmonary bypass and open
heart surgery. Would you continue to routinely use DW-MRI in
your patients after surgery? Are abnormal findings from MRI a
potential marker for subtle neurological injury?
Dr Tedesco. Since the incidence of microemboli after CAS
has been so high, we will continue to monitor our patients that
undergo the procedure. We have now imaged more than 100
routine CEA patients without a single postprocedure microem-
boli, telling us clearly there is a difference between the procedures.
We do believe the microemboli are some sort of marker for brain
injury, and will continue to look closely at long-term effects in
these patients. We already have shown our previous work thatthose with microemboli are more likely to have transient postpro-
cedure neurologic deficits.
DrWei Zhou (Stanford, Calif). The question regarding long-
term neurocognitive effects of subclinical microemboli is an ex-
tremely important one. In fact, our next aim of this on-going study
is to examine whether subclinical microemboli persist and the long
effects of these microemboli. Our plan is to repeatMRI at 1 month
and 6 months after the procedures and to perform neuropsycho-
logical test battery at the same interval. By doing so, we hope to
understand the long-term effect of those microemboli. Again, this
is an important question. Currently, it is still a part of research
protocol, but I think eventually it may become a new outcome
standard for carotid angioplasty and stenting.
Dr James Goff (Albuquerque, NM). Most quality improve-
ment programs are driven by a procedure or process in which you
are having some problem. You nicely presented what you chose to
change, but you did not tell us why you chose those measures. Can
you tell us why you chose those performance measures?
The second question is in your period 2 patients, it looks like you
eliminated predilation of any of the carotid lesions. Butwere there any
patients in whom you did have to predilate to facilitate passage of a
protection device or to facilitate placement of the stent?
You have eliminated the arch arteriogram, but have you also
eliminated the cerebral arteriogram as well? And if you have or have
not, tell me why.
Dr Tedesco.We chose these three particular quality improve-
ment measures after careful interim analysis during our first study
published last year. By univariate analysis, the use of arch angiog-
raphy was associated with a much higher risk of microemboli,
ipsilateral and contralateral, which made some sense, and some
other authors since have confirmed in European series. For this
reason, the routine arch run was taken out of standard protocol.
We chose to heparinize earlier when we realized both hemispheres
were affected, even though we never manipulated one side, and we
began to postulate that catheter trauma along the arch, wire
manipulation, or crossing the orifices of both carotids was poten-
tially a problem. Finally, we became involved in the PROTECT
study, and began using the Abbott Xact stent more often, and
realized we were in effect switching to a closed cell stent system.
In period 2 we did not eliminate predilation. We typically
choose to predilate with a 4  20 mm balloon for all cases. With
regards to the last question, we continue to do pre- and postin-
tracranial runs (Townes view and lateral view) to assure that no
changes in flow have occurred after placement of the stent.
Dr Hasan Dosluoglu (Buffalo, NY). I am impressed at the
amount of contrast you use, 58 cc, I believe. We rarely go above 40
cc. Can this be related to repeat injections between each step
during the stenting procedure? And could these be air emboli that
you are detecting with the MRI?
Dr Tedesco. Potentially, they could be air emboli, although
we really strive to eliminate the incidence of emboli. But we have
also done analysis looking at whether or not contrast volume or
repeat injections were related to microemboli incidence and we
found no association on prior studies.
